Rhythm Pharmaceuticals' Imcivree Could Reach $2 Billion in Worldwide Sales by 2030, RBC Says

MT Newswires Live11-05

Rhythm Pharmaceuticals' (RYTM) Hypothalamic Obesity drug Imcivree could reach over $2 billion in worldwide sales by 2030, RBC Capital Markets analysts said in a Tuesday note.

Analysts said that the company is "pleased" with its Hypothalamic Obesity launch in the United States and does not see cadence slowing into Q4.

Outside the United States, the company views Japan as a larger opportunity than countries like Germany or France due to more attractive pricing and the potential for more rapid diagnosis.

Analysts said that the company's progress in its Prader-Willi Syndrome trial and next-gen agents could drive future upside.

RBC reiterated an Outperform, Speculative Risk rating and a $159 price target on the stock.

Shares of the company were up 5.3% in Wednesday trading.

Price: 93.21, Change: +6.77, Percent Change: +7.83

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment